Elk jaar organiseert de NVTAG een competitie voor de NVTAG prijs (ook wel bekend als de MTA prijs). De winnaar heeft in het voorgaande jaar onderzoek gepubliceerd dat op originele wijze bijdraagt aan de verdere ontwikkeling van onderzoeksmethoden in de MTA. Naast eeuwige roem krijgt de winnaar een geldbedrag van 1,000 Euro met dank aan onze sponsor Bresmed. Hieronder zie je een overzicht van de winnaars van de afgelopen jaren.

Prijswinnaars

2019-2020 Stefan Lipman

QALYs without bias? Nonparametric correction of time trade-off and standard gamble weights based on prospect theory

2018 Giske Lagerweij

A new selection method to increase the health benefits of CVD prevention strategies European Journal of Preventive Cardiology 2018, 25(6) 642–650

2017 Ben Wijnen

A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy.

2016 Janet MacNeil Vroomen

Multiple imputation strategies for zero-inflated cost data in economic evaluations: which method works best? 

2015 Hedwig Blommestein

A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model

2014 Maria Gheorghe

Quality of life and time to death: have the health gains of preventive interventions been underestimated?

2013 Arthur Attema

Prospect theory in the health domain: a quantitative assessment

2012 Aukje van Gestel

van Gestel A, et al. The Role of the Expected Value of Individualized Care inCost-Effectiveness Analyses and Decision Making. Value in Health 2012:13–21.

2010 Ana Bobinac

Bobinac A, et al. Caring for and caring about: Disentangling the family effect and the caregiving effect. Journal of Health Economics 2010; 29: 549-556

2008 Ties Hoomans

Hoomans T et al. Value of information and Value of implementation of an analytic framework to inform resource allocation decisions in metatstatic hormone-refractory prostate cancer. Value in Health 2009; 12; 2; 315-324.

2007 Pieter van Baal

Baal P van, e.a. Unrelated medical care in life years gained and the cost-utility of primary prevention: in search of a ‘perfect’ cost-utility ratio. Health Economics 2007;16: 421-433.

2006 Mandy vd Brink

Brink M van den, e.a.. Cost measurement in economic evaluations of health care: Whom to ask? Medical Care 2004; 42: 740-746.

2005 Silvie van Osch

Osch SMC van e.a. Correcting biases in standard gamble and time trade off utilities. Medical Decision Making 2004; 24: 511-517.

2004 Dennis Stant

Stant A.D. e.a. Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations. Acta Psychiatr Scand. 2003;107(5):361-8.

2003 Jan Oostenbrink

Oostenbrink JB e.a. Standardisation of Costs: the Dutch manual for costing in economic evaluations. Pharmacoeconomics 2002; 20(7):443-54.

2002 Karin Visser

Visser K e.a. Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery: Costs and clinical outcome compared with other surveillance programs’.J. Vasc. Surg. 2001; 33:123-30.

2001 Maiwenn Al

Al M , e.a. Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty”, Health Econ 2000; 9: 599-609.

2001 Sylvia Jansen

Jansen S et al. Unstable preferences: a shift in valuation or an effect of the elicitation procedure? Med Decis Making 2000; 20: 62-71.

2000 Petra van Enckevort

Van Enckevort PJ, et al. Technology assessment of the Dutch Lung Transplantation Program. Int J Technol Assess Health Care 1998; 14: 344-356.

1999 Hans Severens

Severens JL, et al. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther. 1998; 12: 919-923.